Ultragenyx Pharmaceutical appoints Deborah Dunsire to board
Dr. Dunsire brings more than 25 years of management experience in the biopharmaceutical industry.
Prior to joining XTuit in 2017, Dr. Dunsire was president and chief executive officer of FORUM Pharmaceuticals.
From 2005 to 2008, she served as president and chief executive officer of Millennium Pharmaceuticals, Inc.
The company was acquired by Takeda Pharmaceutical Company Limited in 2008, and Dr. Dunsire served as president, CEO and a board member of Millennium: The Takeda Oncology Company until 2013.
Before joining Millennium Pharmaceuticals, Dr. Dunsire led the Novartis U.S. Oncology Business for more than ten years.
She also served on the board of Allergan, Inc. from 2006 to 2015.
Dr. Dunsire has received awards including the 2013 Boston CEO Conference Lifetime Achievement award, the 2011 MassBIO Innovative Leadership Award, the 2009 Healthcare Businesswomen’s Association’s Woman of the Year award, and the 2001 American Cancer Society Excalibur Award.
Dr. Dunsire is a graduate of the medical school of the University of the Witwatersrand, South Africa. ■
LATEST MOVES FROM California
- Peregrine Pharmaceuticals appoints Mark R. Bamforth to boards
- Endologix appoints John Onopchenko as COO
- Depomed appoints Santosh J. Vetticaden as CSO
- Wells Fargo names Michael Roemer as chief compliance officer
- ARMO BioSciences appoints Joseph Leveque as CMO
More inside POST